Financial Performance Forecast - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -485 million and -535 million CNY, compared to a net loss of -398 million CNY in the previous year[4]. - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -550 million and -595 million CNY[4]. - The total profit for the previous year was -404 million CNY, with a net profit attributable to shareholders of the parent company at -398 million CNY[5]. - The financial data in the performance forecast has not been audited by registered accountants and is based on preliminary calculations by the company's financial department[9]. - The company has not identified any significant uncertainties that could affect the accuracy of the performance forecast as of the announcement date[9]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and the final audited financial data will be disclosed in the 2024 annual report[10]. Operational Costs and Investments - The company has increased investment in clinical trials and product registration to enhance competitiveness in core markets, leading to higher R&D expenses[8]. - The company is facing increased operational costs due to the construction of industrial transformation bases and depreciation of fixed and intangible assets[8]. - The company has been actively acquiring and establishing new projects to improve product line and technology layout, which has added to operational costs[8]. - The company is currently in the early investment stage of local production layout overseas to mitigate geopolitical and policy risks[8].
东方生物(688298) - 2024 Q4 - 年度业绩预告